Európai Unió - norvég - EMA (European Medicines Agency)

eli lilly and company limited  - fentanyl - nervesystemet - hunder - for kontroll av smerte assosiert med ortopedisk og bløtvev kirurgi hos hunder.

Norvégia - norvég - Statens legemiddelverk

glenmark arzneimittel gmbh - abirateronacetat - tablett, filmdrasjert - 500 mg

Európai Unió - norvég - EMA (European Medicines Agency)

mylan ireland limited - abirateronacetat - prostata neoplasmer - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Európai Unió - norvég - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateronacetat - prostata neoplasmer - endokrin terapi - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Európai Unió - norvég - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateronacetat - prostata neoplasmer - endokrin terapi - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Európai Unió - norvég - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - miglustat - gaucher sykdom - andre fordøyelseskanaler og metabolisme produkter - miglustat dipharma er angitt for den muntlige behandling av voksne pasienter med mild til moderat type 1-gaucher sykdom. miglustat dipharma kan bare bli brukt i behandlingen av pasienter som enzyme replacement therapy er uegnet. miglustat dipharma er angitt for behandling av progressive nevrologiske manifestasjoner hos voksne pasienter og paediatric pasienter med niemann-pick-type c-sykdom.

Norvégia - norvég - Statens legemiddelverk

dipharma arzneimittel gmbh - nitisinon - kapsel, hard - 5 mg

Norvégia - norvég - Statens legemiddelverk

dipharma arzneimittel gmbh - nitisinon - kapsel, hard - 10 mg

Norvégia - norvég - Statens legemiddelverk

dipharma arzneimittel gmbh - nitisinon - kapsel, hard - 2 mg

Norvégia - norvég - Statens legemiddelverk

dipharma arzneimittel gmbh - nitisinon - kapsel, hard - 20 mg